| Breast Cancer |
1 |
1 |
| Cancer |
0 |
0.67 |
| Cancer Survivor |
0 |
0.57 |
| Antineoplastic Drug |
0 |
0.53 |
| Biologic Therapy |
0 |
0.52 |
| Breast |
0 |
0.48 |
| Endocrine Therapy |
0 |
0.29 |
| Aromatase Inhibitors |
0 |
0.27 |
| Selective Estrogen Receptor Modulators |
0 |
0.26 |
| Cardiometabolic Risk Factors |
0 |
0.99 |
| Hypertension |
0 |
0.23 |
| Lipids Management |
0 |
0.18 |
| Obesity |
0 |
0.18 |
| Cardiovascular Risk Management |
0 |
0.98 |
| Heart Failure (HF) |
0 |
0.17 |
| Dyslipidemia |
0 |
0.16 |
| Cerebrovascular Accident |
0 |
0.14 |
| Body Mass Index |
0 |
0.13 |
| Anthracyclines |
0 |
0.11 |
| Coronary Artery Disease (CAD) |
0 |
0.11 |
| Heart |
0 |
0.11 |
| Stroke Risk |
0 |
0.08 |
| Taxane |
0 |
0.08 |
| Humanized Monoclonal Antibody |
0 |
0.05 |
| Cardiovascular disease |
0 |
0.03 |
| Chemotherapy |
0 |
0.03 |
| Estrogen |
0 |
0.03 |
| Grant |
0 |
0.03 |